New Two-Pronged attack on mouth cancer shows promise
NCT ID NCT05681039
Summary
This study is testing whether adding two immunotherapy drugs (tiragolumab and atezolizumab) before and after standard surgery and chemoradiation can better control advanced oral cavity cancer. It is for adults newly diagnosed with a specific type of tumor (PD-L1 positive) that is still removable by surgery. The main goal is to see if the pre-surgery treatment significantly shrinks the tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.